The reviewers find persistent disease activity and flares despite progress to date. In addition, they point to the persistence of glucocorticoid treatment dependency, comorbidity burden, reduced health-related quality of life, and inconsistent access to high-quality care.
“Bone mineral density screening rates remain low, as do calcium/vitamin D supplementation and primary prophylaxis with anti-osteoporotic therapy," lead author Eileen Rife, MD, said.
An analysis of 34k patients over more than a decade indicates living alone after a hip fracture was associated with a 37% increase in mortality risk among men and a 23% increase in risk among women.
The results of a study presented at ACR 2020 demonstrate that a greater proportion of patients were initiated on denosumab compared with bisphosphonates for the first time—18.5% compared with 16.9%— in 2018.
The US and the world must appreciate the role of the pharmaceutical industry—the investigators, physicians and business leaders—who are rescuing the world from COVID-19. It’s the medical breakthrough of our lifetime.
The IL-23 inhibitor is shown to improve disease activity across joint and skin symptoms.
In part 1 of this article series, Dr. Concoff dusts off the crystal ball to envision the future of the practice of rheumatology, in particular the role of telemedicine during the COVID-19 pandemic and beyond.
Some studies have suggested an increase in the incidence of neuropsychiatric disorders in rheumatic patients may be due to the immunological mechanisms of the disease itself.
Long-term outcomes in systemic lupus erythematosus have improved over time, but unmet needs include glucorticoid dependency and comorbidity burden.
This article features the top 5 stories in Endocrinology Network's coverage of osteoporosis management in 2020.
Although there is no indication that older adults with chronic inflammatory conditions are at higher risk for developing dementing disease, the likelihood is that mild cognitive impairment will show up in your office.
Some of the latest developments in the use of these diagnostic tools for psoriatic arthritis were presented the annual meeting of the American College of Rheumatology Convergence 2020 in November.
“The main take home message is to pay attention to the prevention and treatment of GIOP while prescribing steroids to the patients because the side effects is steroids are not benign," Shikha Singla, MD, said.
The approval was based on findings from the Belimumab International Study in Lupus Nephritis (BLISS-LN) study.
Ixekizumab appears to provide significantly greater simultaneous joint and skin improvement for patients with psoriatic arthritis than adalimumab and doesn’t require combination with methotrexate to boost its efficacy.
Findings from a study presented at ACR 2020 showed a clear difference in co-morbidities and medication use associated with osteoporosis at different lumbar levels. Here, a Q&A with the co-author.
Patients who had received tofacitinib combination therapy may be able to discontinue methotrexate.
The Centers for Medicare & Medicaid Services (CMS) has approved the final physician fee schedule for cognitive care reimbursement in the 2021 Medicare Physician Fee Schedule (MPFS).
The American College of Rheumatology (ACR) issued a statement on Wednesday objecting to a new Centers for Medicare and Medicaid Services (CMS) drug pricing rule the Trump Administration issued in November.
Young men with distal radius fracture are likely to have hormonal imbalances suggests the first study to look at sex hormone levels in younger men experiencing fractures.
Non-heterosexual minority men have a greater risk of poor bone health than heterosexual men, and this risk appears to be independent of lifestyle and psychosocial factors, suggests a study published in the American Journal of Human Biology.
Results from a randomized trial suggest engaging in an exercise program following weight loss surgery could help protect against bone loss.
Positive ACPA status may not necessarily mean a greater likelihood of osteoporosis and fracture for rheumatoid arthritis patients, study shows.
Continued use of low dose glucocorticoid in patients with rheumatoid arthritis also treated with stable DMARD therapy is associated with a small but significant risk of serious infection, show the results of a study published in Annals of Internal Medicine.
An analysis of more than 29k women from two medical centers in California is offering further insight into the effects of discontinuing bisphosphonate treatment in aging women.
Adding rituximab to mycophenolate mofetil may necessitate a lower average daily dose of prednisone in patients with recalcitrant connective tissue disease–associated interstitial lung disease, but the combination treatment may not improve pulmonary function, shows a new study.
Many patients with vasculitis stopped taking immunosuppressive medications, avoided meeting with their doctor in person and failed to follow through on laboratory tests this year due to the COVID-19 pandemic.
A 600-patient trial suggests increased vitamin D supplementation was not associated with a decreased risk of falls but could increase risk of severe falls and fall-related injuries.
It is feasible to discontinue methotrexate in patients who had received tofacitinib combination therapy.
DMARDs improve vascular stiffness in patients with early rheumatoid arthritis regardless of impact on rheumatoid arthritis disease, shows new research published in the Annals of the Rheumatic Diseases.
